title: Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy.
abstract: OBJECTIVE
  To compare the time-to-treatment failure (TTF), overall survival (OS), overall response rate (ORR), and adverse effects of regimens including nedaplatin- or cisplatin-based chemotherapy for advanced breast cancer (ABC).
  
  
  METHODS
  A total of 171 patients with ABC (admission between July 2008 and July 2013) were retrospectively analyzed. Patients received either nedaplatin 75 mg/m(2) (arm N; n = 85) or cisplatin 75 mg/m(2) (arm C; n = 86) in combination with other second-generation chemotherapeutic drugs, such as paclitaxel 175 mg/m(2), docetaxel 75 mg/m(2), gemcitabine 1.25 g/m(2), and navelbine 25 mg/m(2) every 21 days (nedaplatin, cisplatin, paclitaxel, docetaxel on day 1; gemcitabine, navelbine on days 1 and 8). The primary endpoint was TTF in each arm; secondary endpoints were OS, ORR, and toxicity.
  
  
  RESULTS
  In the assessable patient population, in arm N, median TTF and OS was 13.87 months (95% CI: 11.55-16.19) and 31.53 months (95% CI: 28.42-34.64), respectively, with an ORR of 48.2%. In arm C, median TTF and OS was 8.7 months (95% CI: 5.82-11.59) and 24.87 months (95% CI: 18.98-30.75), respectively, with an ORR of 37.2%. The occurrence of grades 3 and 4 hematologic toxicity was more frequent (45.9% vs. 25.6%, p = 0.003) in arm N than in arm C. However, grade ≥2 nonhematologic toxicity was less frequent in arm N than in arm C (12.9% vs. 46.5%, p = 2.05 × 10(-7)).
  
  
  CONCLUSIONS
  Nedaplatin-based chemotherapy regimen was well tolerated and efficiently improved patients' quality of life characterized by prolonged TTF and OS, with a marginal ORR.
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Hui
authors.initials: H
authors.lastname: Pang
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Ting
authors.initials: T
authors.lastname: Feng
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Hailing
authors.initials: H
authors.lastname: Lu
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Qingwei
authors.initials: Q
authors.lastname: Meng
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Xuesong
authors.initials: X
authors.lastname: Chen
authors.affiliation: b Department of Clinical Cancer Prevention , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Shen
authors.affiliation: c College of Medicine, The University of Oklahoma Health Sciences Center , Oklahoma City , Oklahoma , USA.
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Dong
authors.affiliation: a Department of Internal Medical Oncology , Harbin Medical University Cancer Hospital , Harbin , China.
authors.forename: Li
authors.initials: L
authors.lastname: Cai
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D002945:Cisplatin
keywords: Breast cancer; Chemotherapy; Efficacy; Nedaplatin; Toxicity